Table 3 Univariate and multivariate Cox model.

From: Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study

Variable

HR

Lower

0.95

Upper

0.95

p value

Univariable Cox model for PFS

    

Histology PMBCL vs. other LBCL

0.62

0.40

0.98

0.0387

Multivariable Cox model for PFS

Histology PMBCL vs. other LBCL

0.59

0.34

1.04

0.0683

Age 63 vs. 39

1.08

0.71

1.62

0.7282

Disease status relapse vs. refractory

0.74

0.43

1.25

0.2577

Ann Arbor III–IV vs. I–II

1.56

1.01

2.43

0.0473

IPI ≥ 3 vs. < 3

1.26

0.81

1.94

0.3056

Bulky disease yes vs. no

1.75

1.16

2.64

0.0074

ASCT yes vs. no

0.60

0.37

0.99

0.0463

Bridging therapy yes vs. no

0.85

0.52

1.39

0.5122

Univariable Cox model for OS

Histology PMBCL vs. other LBCL

0.38

0.19

0.75

0.0051

Multivariable Cox model for OS

Histology PMBCL vs. other LBCL

0.39

0.17

0.88

0.0227

Age 63 vs. 39

1.15

0.67

1.99

0.6044

Disease status relapse vs. refractory

0.81

0.41

1.59

0.5375

Ann Arbor III–IV vs. I–II

3.00

1.51

5.98

0.0018

IPI ≥ 3 vs. < 3

1.20

0.68

2.10

0.5249

Bulky disease yes vs. no

2.34

1.37

3.98

0.0018

ASCT yes vs. no

0.77

0.42

1.42

0.3975

Bridging therapy yes vs. no

1.62

0.71

3.69

0.2543

  1. PFS progression-free survival, PMBCL primary mediastinal B-cell lymphoma, other LBCL large B-cell lymphoma other than primary mediastinal B-cell lymphoma, HR hazard ratio, IPI international prognostic index, ASCT autologous stem cell transplantation, OS overall survival.
Back to article page